Vaccines against gastroenteritis, current progress and challenges

Enteric viral and bacterial infections continue to be a leading cause of mortality and morbidity in young children in low-income and middle-income countries, the elderly, and immunocompromised individuals. Vaccines are considered an effective and practical preventive approach against the predominant...

Full description

Bibliographic Details
Main Authors: Hyesuk Seo, Qiangde Duan, Weiping Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2020-11-01
Series:Gut Microbes
Subjects:
Online Access:http://dx.doi.org/10.1080/19490976.2020.1770666
_version_ 1818439372574294016
author Hyesuk Seo
Qiangde Duan
Weiping Zhang
author_facet Hyesuk Seo
Qiangde Duan
Weiping Zhang
author_sort Hyesuk Seo
collection DOAJ
description Enteric viral and bacterial infections continue to be a leading cause of mortality and morbidity in young children in low-income and middle-income countries, the elderly, and immunocompromised individuals. Vaccines are considered an effective and practical preventive approach against the predominantly fecal-to-oral transmitted gastroenteritis particularly in the resource-limited countries or regions where implementation of sanitation systems and supply of safe drinking water are not quickly achievable. While vaccines are available for a few enteric pathogens including rotavirus and cholera, there are no vaccines licensed for many other enteric viral and bacterial pathogens. Challenges in enteric vaccine development include immunological heterogeneity among pathogen strains or isolates, a lack of animal challenge models to evaluate vaccine candidacy, undefined host immune correlates to protection, and a low protective efficacy among young children in endemic regions. In this article, we briefly updated the progress and challenges in vaccines and vaccine development for the leading enteric viral and bacterial pathogens including rotavirus, human calicivirus, Shigella, enterotoxigenic Escherichia coli (ETEC), cholera, nontyphoidal Salmonella, and Campylobacter, and introduced a novel epitope- and structure-based vaccinology platform known as MEFA (multiepitope fusion antigen) and the application of MEFA for developing broadly protective multivalent vaccines against heterogenous pathogens.
first_indexed 2024-12-14T17:55:25Z
format Article
id doaj.art-05241bb0c1cd494fbcf414a05e4aa4a0
institution Directory Open Access Journal
issn 1949-0976
1949-0984
language English
last_indexed 2024-12-14T17:55:25Z
publishDate 2020-11-01
publisher Taylor & Francis Group
record_format Article
series Gut Microbes
spelling doaj.art-05241bb0c1cd494fbcf414a05e4aa4a02022-12-21T22:52:33ZengTaylor & Francis GroupGut Microbes1949-09761949-09842020-11-011161486151710.1080/19490976.2020.17706661770666Vaccines against gastroenteritis, current progress and challengesHyesuk Seo0Qiangde Duan1Weiping Zhang2University of Illinois at Urbana-ChampaignUniversity of YangzhouUniversity of Illinois at Urbana-ChampaignEnteric viral and bacterial infections continue to be a leading cause of mortality and morbidity in young children in low-income and middle-income countries, the elderly, and immunocompromised individuals. Vaccines are considered an effective and practical preventive approach against the predominantly fecal-to-oral transmitted gastroenteritis particularly in the resource-limited countries or regions where implementation of sanitation systems and supply of safe drinking water are not quickly achievable. While vaccines are available for a few enteric pathogens including rotavirus and cholera, there are no vaccines licensed for many other enteric viral and bacterial pathogens. Challenges in enteric vaccine development include immunological heterogeneity among pathogen strains or isolates, a lack of animal challenge models to evaluate vaccine candidacy, undefined host immune correlates to protection, and a low protective efficacy among young children in endemic regions. In this article, we briefly updated the progress and challenges in vaccines and vaccine development for the leading enteric viral and bacterial pathogens including rotavirus, human calicivirus, Shigella, enterotoxigenic Escherichia coli (ETEC), cholera, nontyphoidal Salmonella, and Campylobacter, and introduced a novel epitope- and structure-based vaccinology platform known as MEFA (multiepitope fusion antigen) and the application of MEFA for developing broadly protective multivalent vaccines against heterogenous pathogens.http://dx.doi.org/10.1080/19490976.2020.1770666enteric diseasesvaccinologymultiepitope fusion antigen (mefa)enterotoxigenic escherichia coli (etec)vibrio choleraeshigellanontyphoidal salmonellacampylobacterrotavirusnorovirus
spellingShingle Hyesuk Seo
Qiangde Duan
Weiping Zhang
Vaccines against gastroenteritis, current progress and challenges
Gut Microbes
enteric diseases
vaccinology
multiepitope fusion antigen (mefa)
enterotoxigenic escherichia coli (etec)
vibrio cholerae
shigella
nontyphoidal salmonella
campylobacter
rotavirus
norovirus
title Vaccines against gastroenteritis, current progress and challenges
title_full Vaccines against gastroenteritis, current progress and challenges
title_fullStr Vaccines against gastroenteritis, current progress and challenges
title_full_unstemmed Vaccines against gastroenteritis, current progress and challenges
title_short Vaccines against gastroenteritis, current progress and challenges
title_sort vaccines against gastroenteritis current progress and challenges
topic enteric diseases
vaccinology
multiepitope fusion antigen (mefa)
enterotoxigenic escherichia coli (etec)
vibrio cholerae
shigella
nontyphoidal salmonella
campylobacter
rotavirus
norovirus
url http://dx.doi.org/10.1080/19490976.2020.1770666
work_keys_str_mv AT hyesukseo vaccinesagainstgastroenteritiscurrentprogressandchallenges
AT qiangdeduan vaccinesagainstgastroenteritiscurrentprogressandchallenges
AT weipingzhang vaccinesagainstgastroenteritiscurrentprogressandchallenges